Literature DB >> 1404131

Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage.

R A Greenwald1, S A Moak, N S Ramamurthy, L M Golub.   

Abstract

Tetracyclines are potent inhibitors of 2 major matrix metalloproteinases which have been implicated in connective tissue degradation: collagenase and Type IV collagenase/gelatinase. We directly identified these enzyme activities in extracts of inflamed paw tissue from rats with adjuvant arthritis. Oral tetracycline therapy suppressed metalloproteinase activity in arthritic tissue, but even very high doses failed to exhibit substantial antiinflammatory efficacy (reduced joint swelling and paw diameter). Flurbiprofen, a conventional nonsteroidal antiinflammatory drug, reduced inflammatory indices as expected. The combination of the 2 agents administered orally completely inhibited collagenase activity, significantly inhibited gelatinase activity and produced substantial normalization of radiographic joint damage, far greater than either drug alone. Tetracycline inhibition curves in vitro suggest that the collagenase in this tissue is not of fibroblast origin. Tetracycline derivatives might be useful adjuncts to prevention of tissue damage in chronic inflammatory arthritides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404131

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

Review 1.  Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis?

Authors:  J R O'Dell
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 2.  Benefits and risks of minocycline in rheumatoid arthritis.

Authors:  P Langevitz; A Livneh; I Bank; M Pras
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

3.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.

Authors:  J Yrjänheikki; R Keinänen; M Pellikka; T Hökfelt; J Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis.

Authors:  M K Lin; A Katz; H van den Bosch; B Kennedy; E Stefanski; P Vadas; W Pruzanski
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

Review 5.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

6.  Novel antibacterial nanofibrous PLLA scaffolds.

Authors:  Kai Feng; Hongli Sun; Mark A Bradley; Ellen J Dupler; William V Giannobile; Peter X Ma
Journal:  J Control Release       Date:  2010-06-04       Impact factor: 9.776

7.  The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism.

Authors:  S Gilbertson-Beadling; E A Powers; M Stamp-Cole; P S Scott; T L Wallace; J Copeland; G Petzold; M Mitchell; S Ledbetter; R Poorman
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.

Authors:  James L Frazier; Paul P Wang; Daniel Case; Betty M Tyler; Gustavo Pradilla; Jon D Weingart; Henry Brem
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

9.  Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis.

Authors:  A Lauhio; Y T Konttinen; H Tschesche; D Nordström; T Salo; J Lähdevirta; L M Golub; T Sorsa
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 10.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.